Rocío Brea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rocío Brea has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Agustín Lahoz
Biomarkers and Precision Medicine Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
1 shared publication - Alicia María Hidalgo-Estévez
Department of Basic Health Sciences, Universidad Rey Juan Carlos, Alcorcón, Spain, urjc.es
1 shared publication - Apolonia Novillo
Human Genetic Variability Group, Hospital La Paz Institute for Health Research–IdiPAZ (La Paz University Hospital–Universidad Autónoma de Madrid–Getafe University Hospital–Universidad Europea de Madrid), Madrid, Spain
1 shared publication - Carlota Alvarez-Lucena
Instituto de Investigaciones Biomédicas Alberto Sols-Morreale (CSIC-UAM), Arturo Duperier 4, 28029 Madrid, Spain
1 shared publication - Carme Cucarella
Instituto de Biomedicina de Valencia (IBV), CSIC Valencia Spain
1 shared publication - Carmelo García-Monzón
Unidad de Investigación, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
In silico Analysis of CHD4 Mutations Reveals Domain‐Specific Impacts on Cardiovascular Disorders Among Patients With Rare Diseases
Chromodomain‐helicase‐DNA‐binding protein 4 (CHD4) is a critical ATP‐dependent chromatin remodeler that plays fundamental roles in transcriptional repression, DNA damage repair, and lineage specification, making it indispensable for cardiovascular development and function. Pathogenic CHD4 mutations are linked to syndromic and nonsyndromic conditions, often presenting with severe cardiac and vascular anomalies. However, most of these mutations are unique and nonrecurrent, complicating variant classification. In this study, we establish a connection between recent advances in CHD4 structure and function and 36 pathogenic CHD4 mutations associated with rare diseases, including Sifrim–Hitz–Weiss syndrome, moyamoya angiopathy, and childhood idiopathic epilepsy with sinus arrhythmia, all of which exhibited cardiomyopathy, congenital heart defects, and/or vascular abnormalities. Among these mutations, 33 were missense variants, one was an in‐frame small insertion, one, an in‐frame small deletion, and one, a splice‐site variant. Variants were classified according to the ACMG guidelines and subsequent refinements, integrating clinical, functional, population, and in silico (REVEL‐based PP3/BP4) evidence, and cross‐referenced with the ClinVar database to prioritize candidates for further association and functional studies. We classified the missense variants as follows: seven as pathogenic (P), nineteen as likely pathogenic (LP), one as likely benign (LB), and six as variants of uncertain significance (VUS). The splice‐site variant was predicted to cause nonsense‐mediated decay and reduced CHD4 expression, whereas the structural variants were predicted to exert moderate effects on protein function. LP/P variants associated with congenital heart defects were significantly enriched within the ATPase/helicase domain ( p = 0.027), suggesting impairing ATPase motor activity. Nevertheless, several severe heart malformations, including tetralogy of Fallot were linked to pathogenic or LP variants, such as C467Y (plant homeodomain [PHD]), M202I (high‐mobility group [HMG]), and Y1345D (C‐terminal domain). In contrast, other variants located in the N‐ and C‐terminal regions were more often associated with vascular phenotypes, suggesting domain‐specific roles of CHD4 in cardiovascular disease. These findings establish CHD4 as a key regulator of cardiovascular pathophysiology, though a clear genotype–phenotype correlation remains elusive. Further functional validation is essential to elucidate CHD4′s molecular mechanisms, aiding in diagnostic and therapeutic developments.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessIn silico Analysis of CHD4 Mutations Reveals Domain‐Specific Impacts on Cardiovascular Disorders Among Patients With Rare Diseases
Chromodomain‐helicase‐DNA‐binding protein 4 (CHD4) is a critical ATP‐dependent chromatin remodeler that plays fundamental roles in transcriptional repression, DNA damage repair, and lineage specification, making it indispensable for cardiovascular development and function. Pathogenic CHD4 mutations are linked to syndromic and nonsyndromic conditions, often presenting with severe cardiac and vascular anomalies. However, most of these mutations are unique and nonrecurrent, complicating variant classification. In this study, we establish a connection between recent advances in CHD4 structure and function and 36 pathogenic CHD4 mutations associated with rare diseases, including Sifrim–Hitz–Weiss syndrome, moyamoya angiopathy, and childhood idiopathic epilepsy with sinus arrhythmia, all of which exhibited cardiomyopathy, congenital heart defects, and/or vascular abnormalities. Among these mutations, 33 were missense variants, one was an in‐frame small insertion, one, an in‐frame small deletion, and one, a splice‐site variant. Variants were classified according to the ACMG guidelines and subsequent refinements, integrating clinical, functional, population, and in silico (REVEL‐based PP3/BP4) evidence, and cross‐referenced with the ClinVar database to prioritize candidates for further association and functional studies. We classified the missense variants as follows: seven as pathogenic (P), nineteen as likely pathogenic (LP), one as likely benign (LB), and six as variants of uncertain significance (VUS). The splice‐site variant was predicted to cause nonsense‐mediated decay and reduced CHD4 expression, whereas the structural variants were predicted to exert moderate effects on protein function. LP/P variants associated with congenital heart defects were significantly enriched within the ATPase/helicase domain ( p = 0.027), suggesting impairing ATPase motor activity. Nevertheless, several severe heart malformations, including tetralogy of Fallot were linked to pathogenic or LP variants, such as C467Y (plant homeodomain [PHD]), M202I (high‐mobility group [HMG]), and Y1345D (C‐terminal domain). In contrast, other variants located in the N‐ and C‐terminal regions were more often associated with vascular phenotypes, suggesting domain‐specific roles of CHD4 in cardiovascular disease. These findings establish CHD4 as a key regulator of cardiovascular pathophysiology, though a clear genotype–phenotype correlation remains elusive. Further functional validation is essential to elucidate CHD4′s molecular mechanisms, aiding in diagnostic and therapeutic developments.
- Open Access
- 7 June 2024
- Published by Wiley in Liver International
- Vol. 44 (9) , 2409-2423
Beneficial effects of hepatic cyclooxygenase‐2 expression against cholestatic injury after common bile duct ligation in mice
Background and Aims: Cyclooxygenase‐2 (COX‐2) is involved in different liver diseases, but little is known about the significance of COX‐2 in cholestatic injury. This study was designed to elucidate the role of COX‐2 expression in hepatocytes during the pathogenesis of obstructive cholestasis.Methods: We used genetically modified mice constitutively expressing human COX‐2 in hepatocytes. Transgenic mice (hCOX‐2‐Tg) and their wild‐type (Wt) littermates were either subjected to a mid‐abdominal laparotomy or common bile duct ligation (BDL) for 2 or 5 days. Then, we explored the mechanisms underlying the role of COX‐2 and its derived prostaglandins in liver function, and the synthesis and excretion of bile acids (BA) in response to cholestatic liver injury.Results: After BDL, hCOX‐2‐Tg mice showed lower grades of hepatic necrosis and inflammation than Wt mice, in part by a reduced hepatic neutrophil recruitment associated with lower mRNA levels of pro‐inflammatory cytokines. Furthermore, hCOX‐2‐Tg mice displayed a differential metabolic pattern of BA synthesis that led to an improved clearance after BDL‐induced accumulation. In addition, an enhanced response to the BDL‐induced oxidative stress and hepatic apoptosis was observed. In vitro experiments using hepatic cells that stably express hCOX‐2 confirmed the cytoprotective role of prostaglandin E2 against BA toxicity.Conclusions: Taken together, our data indicate that constitutive expression of COX‐2 in hepatocytes ameliorates cholestatic liver injury in mice by reducing inflammation and cell damage and by modulating BA metabolism, pointing to a role for COX‐2 as a defensive response against cholestasis‐derived BA accumulation and injury.
- 7 June 2024
- Published by Wiley in Liver International
- Vol. 44 (9) , 2409-2423
Open AccessBeneficial effects of hepatic cyclooxygenase‐2 expression against cholestatic injury after common bile duct ligation in mice
Background and Aims: Cyclooxygenase‐2 (COX‐2) is involved in different liver diseases, but little is known about the significance of COX‐2 in cholestatic injury. This study was designed to elucidate the role of COX‐2 expression in hepatocytes during the pathogenesis of obstructive cholestasis.Methods: We used genetically modified mice constitutively expressing human COX‐2 in hepatocytes. Transgenic mice (hCOX‐2‐Tg) and their wild‐type (Wt) littermates were either subjected to a mid‐abdominal laparotomy or common bile duct ligation (BDL) for 2 or 5 days. Then, we explored the mechanisms underlying the role of COX‐2 and its derived prostaglandins in liver function, and the synthesis and excretion of bile acids (BA) in response to cholestatic liver injury.Results: After BDL, hCOX‐2‐Tg mice showed lower grades of hepatic necrosis and inflammation than Wt mice, in part by a reduced hepatic neutrophil recruitment associated with lower mRNA levels of pro‐inflammatory cytokines. Furthermore, hCOX‐2‐Tg mice displayed a differential metabolic pattern of BA synthesis that led to an improved clearance after BDL‐induced accumulation. In addition, an enhanced response to the BDL‐induced oxidative stress and hepatic apoptosis was observed. In vitro experiments using hepatic cells that stably express hCOX‐2 confirmed the cytoprotective role of prostaglandin E2 against BA toxicity.Conclusions: Taken together, our data indicate that constitutive expression of COX‐2 in hepatocytes ameliorates cholestatic liver injury in mice by reducing inflammation and cell damage and by modulating BA metabolism, pointing to a role for COX‐2 as a defensive response against cholestasis‐derived BA accumulation and injury.